Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow VIR by emailGet an email when VIR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VIR, unsubscribe in one click. Privacy
📣 What VIR Says Is Next
second half of 2026 · “The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.”
Company press release, Aug 5, 2026 · SEC filing
in 2027 · “The Company anticipates initiating pivotal Phase 3 trials in 2027.”
Company press release, Aug 5, 2026 · SEC filing
first quarter of 2027 · “Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.”
Company press release, Aug 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full VIR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VIR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.